A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
A phase 1/2 trial of Pembrolizumab, Mesna in colorectal cancer and prostate cancer, run by CuraCell TX AB, now recruiting.
Overview
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC is a phase 1/2 interventional study registered as NCT07255664 by CuraCell TX AB, with 12 participants planned, started 2025-11-13 and due to reach its primary completion in 2027-04. Interventions recorded: CC-38, Pembrolizumab, Cyclophosphamid, Interleukin-2, Uromitexan. Conditions listed: Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced. No results are recorded here; the registry entry is the source.
Setting
A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer
Phase
Phase 1/2
Sponsor
CuraCell TX AB
Registry
Enrolled
12